Giles Whalen to Pancreatic Neoplasms
This is a "connection" page, showing publications Giles Whalen has written about Pancreatic Neoplasms.
Connection Strength
1.156
-
Hayward J, Alvarez SA, Ruiz C, Sullivan M, Tseng J, Whalen G. Machine learning of clinical performance in a pancreatic cancer database. Artif Intell Med. 2010 Jul; 49(3):187-95.
Score: 0.264
-
Lim PW, Dinh KH, Sullivan M, Wassef WY, Zivny J, Whalen GF, LaFemina J. Thirty-day outcomes underestimate endocrine and exocrine insufficiency after pancreatic resection. HPB (Oxford). 2016 Apr; 18(4):360-6.
Score: 0.098
-
Flores K, Dinh K, Rouleau E, Whalen G, Wassef W, LaFemina J. Identification of genetic risk for pancreatic adenocarcinoma. Cancer Genet. 2015 Nov; 208(11):559-63.
Score: 0.096
-
Arous EJ, McDade TP, Smith JK, Ng SC, Sullivan ME, Zottola RJ, Ranauro PJ, Shah SA, Whalen GF, Tseng JF. Electronic medical record: research tool for pancreatic cancer? J Surg Res. 2014 Apr; 187(2):466-70.
Score: 0.084
-
Furman MJ, Lambert LA, Sullivan ME, Whalen GF. Rational follow-up after curative cancer resection. J Clin Oncol. 2013 Mar 20; 31(9):1130-3.
Score: 0.079
-
Piperdi M, McDade TP, Shim JK, Piperdi B, Kadish SP, Sullivan ME, Whalen GF, Tseng JF. A neoadjuvant strategy for pancreatic adenocarcinoma increases the likelihood of receiving all components of care: lessons from a single-institution database. HPB (Oxford). 2010 Apr; 12(3):204-10.
Score: 0.065
-
Hill JS, Zhou Z, Simons JP, Ng SC, McDade TP, Whalen GF, Tseng JF. A simple risk score to predict in-hospital mortality after pancreatic resection for cancer. Ann Surg Oncol. 2010 Jul; 17(7):1802-7.
Score: 0.065
-
Murphy MM, Simons JP, Hill JS, McDade TP, Chau Ng S, Whalen GF, Shah SA, Harrison LH, Tseng JF. Pancreatic resection: a key component to reducing racial disparities in pancreatic adenocarcinoma. Cancer. 2009 Sep 01; 115(17):3979-90.
Score: 0.063
-
Hill JS, McPhee JT, Whalen GF, Sullivan ME, Warshaw AL, Tseng JF. In-hospital mortality after pancreatic resection for chronic pancreatitis: population-based estimates from the nationwide inpatient sample. J Am Coll Surg. 2009 Oct; 209(4):468-76.
Score: 0.063
-
Simons JP, Ng SC, Shah SA, McDade TP, Whalen GF, Tseng JF. Malignant intraductal papillary mucinous neoplasm: are we doing the right thing? J Surg Res. 2011 May 15; 167(2):251-7.
Score: 0.062
-
Hill JS, McPhee JT, McDade TP, Zhou Z, Sullivan ME, Whalen GF, Tseng JF. Pancreatic neuroendocrine tumors: the impact of surgical resection on survival. Cancer. 2009 Feb 15; 115(4):741-51.
Score: 0.060
-
Jiang NY, Woda BA, Banner BF, Whalen GF, Dresser KA, Lu D. Sp1, a new biomarker that identifies a subset of aggressive pancreatic ductal adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2008 Jul; 17(7):1648-52.
Score: 0.058
-
McPhee JT, Hill JS, Whalen GF, Zayaruzny M, Litwin DE, Sullivan ME, Anderson FA, Tseng JF. Perioperative mortality for pancreatectomy: a national perspective. Ann Surg. 2007 Aug; 246(2):246-53.
Score: 0.054
-
Yantiss RK, Woda BA, Fanger GR, Kalos M, Whalen GF, Tada H, Andersen DK, Rock KL, Dresser K. KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas. Am J Surg Pathol. 2005 Feb; 29(2):188-95.
Score: 0.046